Sotera Health (SHC) is back in focus after its second quarter 2026 earnings, with the company reporting higher revenue of US$321.38 million and net income of US$53.64 million compared with the prior year.

The earnings release appears to be the main catalyst behind Sotera Health’s recent momentum, with the stock showing a 22.23% 90 day share price return and a 35.00% one year total shareholder return, despite a weaker five year total shareholder return of 22.70%.

If Sotera Health’s earnings story has you watching the sector more closely, it could be a good moment to broaden your search and check out 43 healthcare AI stocks.

Sotera Health’s sharp move after earnings creates a clear gap between the current US$18.86 share price and various fair value estimates. The next step is to identify where that range clusters and how wide the buffer appears.

Most Popular Narrative: 6.7% Undervalued

The most followed narrative places Sotera Health’s fair value at $20.22 per share, slightly above the recent $18.86 close, which frames the current optimism around the stock in a more structured way.

The analysts have a consensus price target of $20.22 for Sotera Health based on their expectations of its future earnings growth, profit margins and other risk factors.

However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $24.0, and the most bearish reporting a price target of just $16.0.

Read the complete narrative. Read the complete narrative.

Want to understand why the story points to a higher valuation for Sotera Health? The core of the narrative rests on the interaction of quicker profit growth, firmer margins, and a valuation multiple that assumes those earnings arrive on schedule. The exact mix of these assumptions is where the real insight sits.

Result: Fair Value of $20.22 (UNDERVALUED)

However, Sotera Health still faces meaningful risks, including higher ethylene oxide compliance and litigation costs, as well as rising competition from alternative sterilization technologies that could pressure future assumptions.

Another View on Sotera Health’s Valuation

The earlier section focused on analyst fair value targets for Sotera Health. Our DCF model suggests a different perspective, with an estimated future cash flow value of $28.53 compared with the current $18.86 share price. On this basis, the stock appears undervalued when assessed using cash flows. Which set of assumptions do you find more reasonable?

Next Steps

With sentiment split between risks and rewards for Sotera Health, it makes sense to move fast and test the assumptions against your own view using the 4 key rewards and 1 important warning sign.

Looking for more Sotera Health style investment ideas?

If Sotera Health has sharpened your focus, do not stop with a single stock. Broaden your watchlist now and give yourself more options before the next move.

• Spot potential bargains early by scanning screener containing 21 high quality undiscovered gems that pair solid fundamentals with relatively low market attention.
• Strengthen your defense by reviewing 83 resilient stocks with low risk scores that aim to keep volatility and risk scores in check.
• Target resilient financial footing by focusing on solid balance sheet and fundamentals stocks screener (48 results) that emphasize cash strength and manageable debt.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.